Navigation Links
Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations

FRANKFURT, Germany, February 25 /PRNewswire/ -- t2cure, a clinical stage biopharmaceutical company developing novel regenerative therapies based on autologous progenitor cells, announced today that it has appointed Dr. Petra Rueck Head of Clinical Operations.

"We are pleased to have Petra join our company", said Manfred Ruediger, CEO of t2cure. "Petra's experience in clinical research and project management will be of critical importance to t2cure as we are preparing to move our lead product into Phase III clinical trials for severe infarcts."

"It is a unique opportunity to contribute to the development of therapies that have the potential to significantly improve patient outcomes", said Petra Rueck. "t2cure's clinical candidates have demonstrated their capacity to increase the regenerative potential of tissue damaged by acute myocardial infarctions and other cardiac or peripheral vascular diseases."

Prior to joining t2cure, Dr Rueck was a project leader with ratiopharm's Biogenerix AG, Mannheim, where most recently she was responsible for a biotechnology project including the design and management of preclinical and clinical development programs. Her previous experience includes positions in clinical research management at Pfizer and Intervet. Before that, Dr. Rueck was assistant professor at Berlin University Hospital "Benjamin Franklin" (now Charite) and worked as postdoctoral researcher at INSERM, Paris. Petra Rueck received her PhD degree in pharmacology from the University of Giessen, Germany, where she studied veterinary medicine.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy). The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development and will enter Phase III soon. t2cure is privately financed with Entrepreneurs Fund BV, Amsterdam as lead investor.


Manfred Ruediger, CEO

t2cure GmbH

Bettinastrasse 35-37

D-60325 Frankfurt am Main

Tel: +49-69-75-61-46-87-0

Fax: +49-69-75-61-46-87-9


SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
2. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
3. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
4. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
5. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
6. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
7. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
8. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
10. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
11. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
Breaking Biology Technology:
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
(Date:10/23/2015)... and GOLETA, California , October 23, ... BIOPAC and SensoMotoric Instruments (SMI) announce a mobile plug ... data captured during interactive real-world tasks SensoMotoric ... integration of their established wearable solutions for eye tracking ... gaze behavior captured with SMI Eye Tracking Glasses ...
(Date:10/22/2015)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 30, 2015. --> --> ... percent over the comparable quarter last year to $470.0 million. Net ... or $0.62 per diluted share. --> ... fiscal 2016 grew 39 percent over the prior year period to ...
Breaking Biology News(10 mins):